期刊文献+

尿激酶型纤溶酶原激活剂(uPA)和其受体(uPAR)在肝细胞癌的表达及其临床和病理意义 被引量:7

Expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in hepatocellular carcinoma and its clinical and pathological significance
暂未订购
导出
摘要 目的 研究尿激酶型纤溶酶原激活剂 (uPA)和其特异性受体 (uPAR)在肝细胞癌 (HCC)的表达及其临床和病理意义。 方法 应用免疫组织化学和酶联免疫吸附法 (ELISA)检测uPA和uPAR在HCC和非癌组织中的表达 ,并与临床及病理指标相联系。 结果 HCC中uPA和uPAR的阳性表达率分别为 75 0 % (12 / 16 )和 6 8.8% (1/ 16 )。在进展性和侵袭性肿瘤与非进展性和非侵袭性肿瘤间uPA和uPAR阳性率无显著性差异 (P >0 .0 5 )。阳性染色主要位于癌细胞和基质细胞胞浆且主要位于癌侵犯的边缘。非癌组织仅见少量阳性染色细胞 ,对照组无特异性阳性染色。在ELISA中 ,癌与非癌组织uPA抗原水平分别为 (4 2 3± 0 5 7)ng/mg蛋白和 (1 2 6± 0 14)ng/mg蛋白 ,uPAR抗原水平分别为 (4 2 5± 0 2 1)ng/mg蛋白和 (3 15± 0 2 3)ng/mg蛋白 ,有显著性差异 (t=18.96 3,P =0 .0 0 0 ;t=13.6 93 ,P =0 .0 0 0 )。且进展性和侵袭性肿瘤中其抗原水平显著高于非进展性和非侵袭性肿瘤 (P <0 0 5 )。  结论 uPA和uPAR在肝细胞癌表达较高并与其进展和侵袭密切关联。 Objective To investigate expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in hepatocellular carcinoma(HCC) and its clinical and pathological significance. Methods The expression of uPA in cancer and non-cancer samples of 16 cases of hepatocellular carcinoma was detected by immunohistochemistry and ELISA. Clinical and pathological features were associated with experimental data. Results The rates of positive expression of uPA and uPAR in cancer tissues were 75 0%(12/16) and 68.8%(11/16) respectively. The rates of positive uPA and uPAR between progressive and aggressive tumors and non-progressive and non- aggressive tumors didn't show significant difference ( P >0.05). Positive stains were located in cytoplasm of cancer and stromal cells, especially in invasive margin of cancer. Slight positive stains were observed in non-cancer tissues. But in the control samples, there wasn't specific stain. In ELISA, the uPA antigen levels in cancer and non- cancer tissues were (4.23±0.57)ng/mg protein and (1.26±0.14)ng/mg protein; the uPAR antigen levels in caner and non-cancer tissues were(4.25±0.21)ng/mg protein and (3.15±0.23)ng/mg protein respectively. Significant difference existed in both uPA and uPAR antigen levels in these two kinds of tissue ( t=18.963,P=0.000;t=13 693,P=0 000 ). Furthermore, these antigen levels in progressive and aggressive tumors significantly higher than those in non-progressive and non-aggressive tumors ( P <0.05) Conclusions uPA and uPAR have high expression in HCC tissues and close relations with the progression and aggression of HCC.
出处 《中国微创外科杂志》 CSCD 2002年第6期422-423,共2页 Chinese Journal of Minimally Invasive Surgery
关键词 尿激酶型纤溶酶原激活剂 受体 肝细胞癌 病理学 临床意义 ELISA 免疫组织化学 Urokinase-type plasminogen activator(uPA) Urokinase-type plasminogen activator receptor(uPAR) Hepatocellular carcinoma
  • 相关文献

参考文献6

  • 1Knoop A, Andreasen PA, Andersen JA, et al. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer, 1998, 77:932-940.
  • 2Suzuki S, Hayashi Y, Wang Y, et al. Urokinase type plasminogen activator receptor expression in colorectal neoplasms. Gut, 1998, 43:798-805.
  • 3Nakajima M, Chop AM. Tumor invasion and extracellular matrix degradative enzyme: regulation of activity by organ factors. Semin Cancer Biol, 1991, 2:115-127.
  • 4Jankun J, Merrick HW, Goldblatt PJ. Expresion and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. Cell Biochem, 1993, 53:135-144.
  • 5Ellis V, Behrendt N, Dano K. Plasminogen activation by receptor-bound urokinase: A kinetic study with both cell-associated and isolated receptor. J Biol Chem, 1991, 266:12752-12758.
  • 6Miyake H, Hara I, Yamanaka K, et al. Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int J Oncol, 1999, 14:535-541.

同被引文献62

  • 1潘元青,孙少华,马岚.恶性肿瘤中TGF-β_1信号传递分子DPC4/Smad4的研究进展[J].肿瘤防治杂志,2004,11(4):414-417. 被引量:1
  • 2张用书,李秀珍.尿激酶分子系统与肿瘤[J].军事医学科学院院刊,1996,20(3):220-223. 被引量:5
  • 3Nakata S, Ito K, Fujimori M, et al. Involvement of vascular endothelial growth factor and urokinase- type plasminogen activator receptor in microvessel invasion in human colorectal cancers [ J ]. Int J Cancer, 1998,79 (2) : 179 - 186.
  • 4Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activator system in tumor invasion and metastasis :prognostic relevance and target for therapy [ J ]. Thromb Haemost, 1997,78 ( 1 ) : 285 - 291.
  • 5Marisa A, Gallicchio, Ghristoph K,et al. Urokinase type plasminogen activator receptor is involved in insulin -like growth factor-induced migration of rhabdomyosarcoma cells in vitro[J]. J Cell Physiol, 2003,197( 1 ) : 131 -138.
  • 6Strauss BH,Lau HK,Bowman KA,et al. Plasma urokinase antigenand plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis[J].Circulation, 1999,100:1616.
  • 7Pedersen H, Grondahl-Hansen J, Franis D, et al.Urokinase and ptas-minogen activator inhibitor type 1 in pulmonary adenocarcioma[J]. Cancer Res, 1994,54(1): 120.
  • 8Bouchet C, Hacene K, Martin PM,et al.Dissemination risk index based on plasminogen activator system components in primary breast cancer[J].J Clin Oncol, 1999,17(10) : 3048.
  • 9Macchione E ,Epifano O ,Stefanini M ,et al. Urokinase redistribution from the secreted to the cell-bound fraction in granulose cells of rat preovulatory follicles[J].Biol Reprod ,2000,62(4):895.
  • 10SJAM G, CORNELIS F M S, MARTINE M H, et al. Prognostic value of the plasminogen activation system in patients with gastric carcinoma[J]. Cancer, 1996, 77:1 035-1 043.

引证文献7

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部